Sixteen received treatment after they redeveloped SCLC while four did not. Eleven patients were retreated with chemotherapy alone, two patients received chemotherapy plus chest radiotherapy, one patient received radiotherapy alone, one patient underwent lobectomy, and one patient was treated with a monoclonal antibody followed by chemotherapy. Nine of 16 patients (56%) treated after they redeveloped SCLC had an objective response (3 complete and 6 partial). The median survival of all 20 patients after they redeveloped SCC was 3.9 months (range, 0 to 46 months). The median survival of the patients who were retreated was 6.5 months (range, 1 to 46 months). Conclusions: Patients who suffer relapses with SCLC 2 or more years from diagnosis are candidates for retreatment. (CHEST 1996; 110:165-71) 
There are relatively little data on the results of subsequent treatment of these patients.
A prior report in 1983 of 6 patients from this institution described the initial experience with retreatment of patients surviving SCLC for 2 or more years. Four of the 6 patients retreated with combination chemotherapy had a partial or complete response and achieved a median survival of 10 months from the start of retreatment. 7 This success in retreatment is in contrast to the experience with patients with SCLC whose cancer relapses shortly after induction therapy in whom retreatment has been only minimally suc- cessful.8 '9 initial treatment.10-14 Therefore, more patients are at risk for late relapses of SCLC. In addition, most patients with limited-stage disease have been initially treated with chemotherapy plus chest radiotherapy which causes more hematologic toxicity than chemotherapy alone. '15"6 The increased use of combinedmodality therapy will likely reduce a patient's ability to tolerate retreatment with chemotherapy.
We have identified patients who have redeveloped small cell cancer (SCC) after surviving cancer free for 2 or more years from their initial treatment. The outcome of all patients who redeveloped SCC has been followed, including both those who received retreatment and those who did not. The patient characteristics, regimens administered, hematologic toxic reactions encountered, response to therapy, and survival duration before and after redevelopment of SCC were determined for each patient.
MATERIALS AND METHODS Patient Population
Patients with histologically confirmed, previously untreated SCLC were enrolled on National Cancer Institute (NCI) intramural therapeutic trials between 1973 and 1993 . These trials were approved by the Institutional Review Boards at the NCI, National Naval Medical Center, and the Washington, DC 20 patients, including those who did not receive retreatment, was 3.9 months (range, 0 to 46 months) (Fig 1) . Six ofthe 20 patients (30%) survived more than 1 year from the time of redevelopment of SCLC, and 2 patients (10%) survived more than 2 years beyond the date of redevelopment. One of these 2 patients died from recurrent SCLC 26 months after treatment at relapse and the other patient remained without evidence of SCLC at the time of her death from bacterial peritonitis 46 months later (Fig 2) .
The median survival from the time of redevelopment of SCLC of the 16 patients who were retreated was 6.5 months (range, 1 to 46 months). Analysis of survival based on patient response reveals that the median survival of the 3 patients who achieved complete response was 26 months; the median survival of the 6 patients who achieved partial response was 10 months; and the median survival of those 7 patients who had no response to retreatment was 4 months. The median survival ofthe 13 patients who received chemotherapy with or without radiotherapy was 4.4 months (range, 1 to 46 months). The median survival of the 15 patients with performance status 0 to 2, including three patients who were not retreated, was 7.2 months.
Analysis of patients based on the retreatment regimen received shows that the 8 patients retreated with etoposide-based chemotherapy had a median survival of 11 months and the 8 patients who received nonetoposide-based treatment (including radiation and surgery) had a median survival of5.5 months (p=0.056).
Seven of 13 patients (54%) who received chemotherapy developed grade 4 or 5 leukopenia from reinduction therapy at the time of redevelopment of SCLC. Two of the 13 patients (15%) who underwent retreatment died from infections that were directly related to treatment-induced neutropenia. Six of the 7 patients (86%) who developed grade 4 or 5 hematologic toxicity during retreatment had received combined modality therapy during their initial treatment of SCLC. Two patients developed grade 3 leukopenia during retreatment and the remaining 4 probabilities for initially treated patients with both limited-and extensive-stage SCLC. "12 It has been suggested previously that the duration of first response to chemotherapy for SCLC is a predictor of the outcome of retreatment at the time of relapse.9 We have examined the Southwest Oncology Group (SWOG) experience in retreating 67 patients with SCLC who suffered relapses or progressed within a median time of 6 weeks (range, 3 to 28 weeks) from the completion of induction chemotherapy. Forty-six of 67 patients (69%) were initially treated with regimens containing EP, and 21 (31%) were treated with other chemotherapy regimens. Twenty-seven patients (39%) were initially treated with combination chemotherapy and chest radiotherapy. Only 3 of the 67 (4%) patients retreated with cyclophosphamide-based chemotherapy at the time of relapse in this study achieved an objective response. The median survival from the start of retreatment for this group was 10 weeks.8 The patients were in poor physical condition because nearly half of the patients (46%) in the SWOG study had a performance status of 2 to 4 at the time of relapse. A European Organization for Research and Treatment of Cancer (EORTC) study also examined the outcome of 18 patients with performance status 0 to 3 who suffered relapses with SCLC after a median initial response of less than 34 weeks following treatment with cyclophosphamide, doxorubicin, and etoposide. In this study, 8 of 18 patients (44%) had an objective response to retreatment with cyclophosphamide, doxorubicin, and etoposide and the median survival from the start of retreatment was 17 weeks.9 Comparison of these three treatment groups is difficult given the differences in performance status and treatment regimens in each CHEST! 1 10 / 1 /JULY, 1996 169 group. Although the response rate in our retreated patients is higher than the response rate in the SWOG cohort (NCI 56% vs SWOG 4%; p<0.0001), it is not significantly different than the EORTC cohort (NCI 56% vs EORTC 44%; p=0.73). The median survival in each group of retreated patients does not appear to be significantly different (NCI 6.7 months vs SWOG 2.5 months vs EORTC 4.2 months). A direct statistical comparison of the survival duration of these three cohorts cannot be done since we have extracted the SWOG and EORTC results from published articles and the individual patient data from these studies are not available.8 '9 The objective tumor response after retreatment of late redevelopment of SCLC with agents previously utilized during initial therapy is similar to the experience in salvage therapy of Hodgkin's disease.30 Fourteen of 19 patients (74%) with Hodgkin's disease described by Longo et al30 who suffered relapses greater than 1 year from initial diagnosis responded to the identical chemotherapy regimen they had received during initial treatment. The survival duration in these patients was significantly longer than the survival duration of patients with Hodgkin's disease who suffered relapses less than 1 year from initial diagnosis.30 Sim Two-year survivors of SCLC who redevelop SCLC appear to respond to repeated administration of chemotherapy at a higher rate than patients with earlier redevelopment of the disease. As seen in patients with Hodgkin's disease, the tumor response to retreatment in patients with late redevelopment of SCC is generally less impressive and shorter in duration than the initial response to therapy at first diagnosis. The short median survival in patients who redevelop SCLC is most likely because the disease is more often recurrent rather than a second primary cancer. We have previously shown that the 18 patients who developed recurrent SCLC followed a typical pattern of recurrence.3 Seven re-presented with cancer in the initial lobe plus regional lymph nodes, five in the initially involved lymnph nodes plus distant sites, and six in distant sites alone. We believe that the recurrence of SCLC represents a regrowth of residual SCLC cells that took place after chemotherapy was discontinued. We hypothesize that the regrowth of the tumor over this period of time has allowed a redevelopment of tumor heterogeneity so a significant proportion of the SCLC cells are once again sensitive to readministration of combination chemotherapy. Therefore, many of our patients have had a tumor response after retreatment.
The data presented herein and the data from the literature allow us to make the following recommendations: patients with a performance status of 0 to 2 who redevelop SCLC 2 or more years after initial treatment should be retreated with combination chemotherapy. Certain patients, especially those previously treated with combined modality therapy, are likely to develop grade 3 and 4 hemnatologic toxic reactions. Therefore, we recommend that physicians initially use chemotherapy regimens that are unlikely to cause severe hematologic toxicity.
